Clasificación en acciones
#27154
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Precio por acción
$3.17
Última sincronización: 2021-08-31
Capitalización bursátil
$34.83M
Comercio Cytocom, Inc. (CBLI)
Precio CBLI con Capital del mercado a B
Capitalización de mercado de Cytocom, Inc.(CBLI)
Capitalización bursátil: $34.83M
A fecha de August 2026, Cytocom, Inc. tiene una capitalización de mercado de $34.83M. Esto convierte a Cytocom, Inc. en la 27154th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Cytocom, Inc. desde 2006 hasta 2026
CBLI en comparación con los más populares 5 títulos stocks
| Precio por CBLI |
|
Activo B |
Capital del mercado en B |
Resultados |
|
|
|
|
$5.301T
|
+15,218,469.34%
|
|
|
|
|
$4.634T
|
+13,303,540.65%
|
|
|
|
|
$4.143T
|
+11,894,223.84%
|
|
|
|
|
$3.589T
|
+10,304,838.43%
|
|
|
|
|
$2.857T
|
+8,202,079.53%
|
